LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market 2016-2020 to grow at a CAGR of 1.3% during the forecast period, according to their latest report.
The research study covers the present scenario and growth prospects of the global MRSA drugs market for 2016-2020. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors operating in the global MRSA drugs market. Most importantly, the report outlines the pipeline products under various stages of development in the market. In addition, it provides valuable insights, which includes mechanism of action (MOA), route of administration, and R&D brief for Phase III and registration stage molecules.
Technavio healthcare and life sciences analysts highlight the following four factors that are contributing to the growth of the global MRSA drugs market:
- Special regulatory designations
- Increasing prevalence of infections
- Growing awareness of diseases
- Rise in older population
Special regulatory designations
The rise in the development of multidrug-resistant pathogens, coupled with the limited number of drugs available for treatment, has resulted in the generating antibiotics incentives now (GAIN) Act by the FDA. As per this act, any drug being developed to treat qualified infectious diseases will be granted a qualified infectious disease product (QIDP) designation, which will help the company attain fast track designation and priority review for the drug. Thus, the drug will be developed and released into the market at a faster rate. The FDA provides fast track and orphan drug designations to drugs that treat serious diseases and address unmet medical needs, leading to rapid development of medications. The designation includes benefits such as the eligibility for priority review for new drug application (NDA) if relevant criteria are met.
For instance, Dalvance, a second-generation lipoglycopeptide antibiotic, received QIDP designation due to which it received priority review and was approved by the FDA on May 2014. This helps in the faster entry of the drugs into the market, thus boosting market growth.
Increasing prevalence of infections
Infectious diseases are caused by pathogens and can be transmitted from person to person through direct or indirect contact. Demographic changes caused by increased globalization and urbanization have led to the global emergence of these diseases. High population densities favor colonization of disease pathogens and their persistence among human population.
An expansion of human cities has negatively affected our ecosystems and natural landscapes. For instance, deforestation destroys the natural habitats of animals, which now localize near human habitats. Often these animals are vectors for pathogen transmission, and their movements near human habitats pose a risk of infection transmission to humans. The growing number of dams, poor living conditions, lack of sanitation, and inadequate waste management systems have also increased the incidence and prevalence of diseases. “Changes in environmental conditions and the increase in trade and travel are also contributing to the increase in the occurrence of infectious diseases,” says Barath Palada, a lead analyst at Technavio for infectious and rare diseases research.
Growing awareness of diseases
Early detection of infectious diseases is important to reduce the chances of severe damage to the body. Awareness of diseases has increased the use of drugs to treat them in the early stages, preventing complications. October is celebrated as World MRSA Awareness Month. European Antibiotic Awareness Day was celebrated on November 18, 2014 to raise awareness of antibiotic resistance and promote judicious use of antibiotics.
Other awareness programs include World Hand Hygiene Day on May 5, National Infection Control Week in the third week of October, World Pneumonia Day on November 12, and Antibiotic Awareness Week in the third week in November. These programs help increase the treatment seeking population, thus driving the market.
Rise in older population
It has been observed that the older (>60 years) population is highly susceptible to MRSA infections, especially in the hospital settings as their compromised immune systems makes them prone to diseases and infections. According to WHO, the population under this age group is likely to reach two billion by 2050. “The World Population Aging report of the United Nation, published in 2013, sets forth that the proportion of the older people was high in developing nations as compared to developed countries. This is expected to increase the chances of infection, thereby leading to market growth,” says Barath.
Browse Related Reports:
- Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020
- Global Allergy Immunotherapies Market 2016-2020
- COPD Drugs Market in China 2016-2020
Do you need a report on a market in a specific geographical cluster or country but can’t find what you’re looking for? Don’t worry, Technavio also takes client requests. Please contact email@example.com with your requirements and our analysts will be happy to create a customized report just for you.
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.